Inhibikase Therapeutics

Inhibikase Therapeutics, Inc. provides infectious disease treatments. It develops small molecule platform for treating both bacterial and viral infectious diseases. It operates through RAMP™ Drug Innovation Engine technology. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inhibikase Therapeutics advances trials amidst safety concerns and financial stability

Inhibikase Therapeutics made progress in trials but faces safety concerns and financial challenges.
Opportunities lie in advancing Phase III plans and clinical development for potential market growth.
The company's near-term milestones and financial stability are key areas to watch for future performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.

Century Communities

Eldorado Gold

Southside Bancshares

Third Coast Bancshares

EGO, SBSI, CCS, TCBX and IKT have been added to the Zacks Rank #1 (Strong Buy) List on February 6, 2023.

New Strong Buy Stocks for February 6th

ADMA Biologics

Ekso Bionics Hlds

ADMA, EKSO and IKT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 31, 2024.

Best Momentum Stocks to Buy for January 31st

Anavex Life Sciences

ADMA, IKT, YPF, AVXL and EKSO have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.

New Strong Buy Stocks for January 31st

BOSTON and ATLANTA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced a publication of Phase 1 clinical studies with risvodetinib (“risvo”), a potential disease-modifying therapy for Parkinson's disease and related disorders. The publication entitled “A Phase I, Randomized, SAD, MAD, and PK Study of Risvodetinib in Older Adults and Parkinson's Disease” was published online in the peer reviewed Journal of Parkinson's Disease (DOI: 10.3233/JPD-230319) on January 13, 2024.

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

PACCAR

PagerDuty

PCAR, IKT and PD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 26, 2023.

Best Momentum Stocks to Buy for January 26th

MongoDB

IKT, EGO, MDB, PD and AVXL have been added to the Zacks Rank #1 (Strong Buy) List on January 26, 2023.

New Strong Buy Stocks for January 26th

Inhibikase Therapeutics, Inc. (IKT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Inhibikase Therapeutics, Inc. (IKT) Upgraded to Buy: What Does It Mean for the Stock?

Joseph Frattaroli to retire at end of 1Q24; Garth Lees-Rolfe, Vice-President of Finance, to be promoted to Chief Financial Officer Joseph Frattaroli to retire at end of 1Q24; Garth Lees-Rolfe, Vice-President of Finance, to be promoted to Chief Financial Officer

Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli

- Pre-NDA Meeting to discuss requirements for a 505(b)(2) NDA submission for IkT-001Pro in up to eight blood and stomach cancer indications -

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q3 2023 Earnings Conference Call November 15, 2023 8:00 AM ET Company Participants Alex Lobo - IR Milton Werner - CEO Joseph Frattaroli - CFO Conference Call Participants Edward White - H.C. Wainwright Operator Hello, and welcome to the Inhibikase Therapeutics Third Quarter 2023 Financial Results.

Inhibikase Therapeutics, Inc. (IKT) Q2 2023 Earnings Call Transcript

Company to host conference call on Wednesday, November 15, 2023 at 8:00 a.m. ET Company to host conference call on Wednesday, November 15, 2023 at 8:00 a.m. ET

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

This release corrects and replaces the headline in the release that was disseminated on November 7, 2023. The reason for this correction is to fix the title which previously stated, "second quarter" rather than "third quarter."

Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023

BOSTON and ATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (“PD”), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today highlighted an analysis of eleven unblinded participants from the 201 Trial evaluating risvodetinib (IkT-148009) in untreated Parkinson's disease. These participants were withdrawn from the trial following the FDA's temporary clinical hold in November, 2022 that was lifted in January, 2023. The Company also provided an update on the enrollment progress and recruitment tools being used in the ongoing 201 Trial.

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson's Disease and Provides Update on Ongoing Enrollment

BOSTON and ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that risvodetinib (IkT-148009) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Multiple System Atrophy (MSA).

Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy

- New tablet formulation of risvodetinib approximately doubles drug exposure at same dose – - Tablet formulation to be evaluated in the planned 12-month extension portion of the 201 trial– BOSTON and ATLANTA , Aug. 24, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has developed a novel tablet formulation of IkT-148009, designed to improve drug exposure and overcome existing challenges related to patient use. "As we advance our 201 trial evaluating risvodetinib at 50, 100 and 200 mg to treat Parkinson's disease, we have continued to expand our formulation and delivery capabilities," commented Dr. Milton Werner, President & CEO of Inhibikase.

Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib

BOSTON and ATLANTA , Aug. 22, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase, will deliver two oral presentations at the International Congress of Parkinson's Disease and Movement Disorders.

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders

- Company to assess new molecules arising from internal discovery and other companies to enhance suppression of neurodegeneration through c-Abl inhibition – - Selected non-proprietary name risvodetinib for IkT-148009 evocative of 'reversal' - BOSTON and ATLANTA , Aug. 21, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, is evaluating new molecules with multiple mechanisms of action for c-Abl inhibition. Along with the development of new molecules, IkT-148009 has now been granted the non-proprietary name of risvodetinib (or 'risvo').

Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib

- 600 mg IkT-001Pro demonstrated bioequivalence to Standard-of-Care 400 mg Dose of Imatinib mesylate - - Minimal adverse events with consistent drug delivery seen across 31 subjects in the pivotal trial - - Company to submit FDA meeting request to discuss regulatory approval pathway - BOSTON and ATLANTA , Aug. 17, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced the completion of its bioequivalence study of IkT-001Pro compared to 400 mg imatinib mesylate. "We are pleased to announce the completion of the pivotal phase of our 501 study evaluating IkT001Pro," stated Dr. Milton Werner, President and Chief Executive Officer of Inhibikase Therapeutics.

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro

BOSTON and ATLANTA , Aug. 7, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the second quarter ended June 30, 2023, on Monday, August 14, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m.

Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023

BOSTON and ATLANTA , July 17, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it received written notice on July 17, 2023 from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (Nasdaq) indicating that Inhibikase Therapeutics has regained full compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2), and that Inhibikase is in compliance with all applicable listing standards. About Inhibikase ( www.inhibikase.com )       Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders.

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

BOSTON and ATLANTA, June 29, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will effect a 1-for-6 reverse stock split of its common stock. The reverse stock split will become effective at 12:01A.M June 30, 2023.

Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split

- 600 mg dose of IkT-001Pro selected as the bioequivalent dose relative to standard of care 400 mg imatinib mesylate - - On-track to complete pivotal clinical phase of the 501 study by the end of 2Q22 - BOSTON and ATLANTA , June 22, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has selected the bioequivalent dose of IkT-001Pro, the Company's prodrug formulation of imatinib mesylate designed to enhance the safety and efficacy of imatinib (marketed as Gleevec®) in patients with Chronic Myelogenous Leukemia (CML) and provided an update on its '501' bioequivalence study. The '501' bioequivalence study has evaluated IkT-001Pro at four single ascending doses of 300, 400, 500 and 600 mg, leading to the selection of 600 mg IkT-001Pro as the bioequivalent dose to 400 mg imatinib mesylate.

Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

- Company to highlight the '201' trial at multiple regional seminars for physicians - - Up to 61% of clinical sites actively screening patients by close of 2Q23 - BOSTON and ATLANTA , June 21, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced a physician and patient awareness campaign for its Phase 2 '201' program evaluating IkT-148009 as a potentially disease-modifying treatment of Parkinson's disease. Dr. Milton Werner, President & CEO of Inhibikase Therapeutics will present to community neurologists and movement disorder specialists at multiple regional seminars where the Company has activated clinical trial sites.

Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease

BOSTON and ATLANTA , May 30, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that Dr. Milton Werner, Ph.D., President & Chief Executive Officer of Inhibikase, will deliver a presentation at the LD Micro Invitational XIII Conference being held on June 6-8, 2023, in Los Angeles, California.

Inhibikase Therapeutics to Present at the LD Micro Invitational XIII

Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q1 2023 Earnings Conference Call May 16, 2023 8:00 AM ET Company Participants Alex Lobo - Stern IR Milton Werner - President & CEO Joseph Frattaroli - CFO Conference Call Participants Edward White - H.C. Wainwright Operator Good morning and welcome to the Inhibikase Therapeutics First Quarter 2023 Financial Results Conference Call.

News for Inhibikase Therapeutics Stock (IKT)